Literature DB >> 10622800

Severity of illness and profitability: a patient level analysis.

C E Carpenter1, M D Rosko, D Z Louis, E J Yuen.   

Abstract

Crafting a payment mechanism for hospitals that provides for the legitimate operating needs of efficient institutions is an enduring health policy dilemma. The Prospective Payment System used by Medicare and some other payers in the US has been criticized for not adjusting for differences in severity of illness within diagnosis-related groups (DRGs). Previous studies have examined the relationship between profitability and severity of illness at the hospital level. This study examines the relationships between severity of illness and cost, revenue, and profit at the patient level. Two measures of severity (disease stage and number of unrelated diseases) were significant predictors of cost per case, and often had better predictive power than DRGs. In most instances, payers did not compensate adequately for severity so that higher values for the severity variables resulted in financial losses for the hospital.

Entities:  

Mesh:

Year:  1999        PMID: 10622800     DOI: 10.1177/095148489901200403

Source DB:  PubMed          Journal:  Health Serv Manage Res        ISSN: 0951-4848


  4 in total

1.  The risk-adjusted vision beyond casemix (DRG) funding in Australia. International lessons in high complexity and capitation.

Authors:  Kathryn M Antioch; Michael K Walsh
Journal:  Eur J Health Econ       Date:  2004-06

2.  Risk adjustment policy options for casemix funding: international lessons in financing reform.

Authors:  Kathryn M Antioch; Randall P Ellis; Steve Gillett; Daniel Borovnicar; Ric P Marshall
Journal:  Eur J Health Econ       Date:  2007-02-02

3.  The effects of case mix on hospital costs and revenues for medicare patients in California.

Authors:  Keon-Hyung Lee
Journal:  J Med Syst       Date:  2007-08       Impact factor: 4.460

4.  Measuring case severity: a novel tool for benchmarking and clinical documentation improvement.

Authors:  Jie Xiang; Paul W Durance; Louisa C Griffes; Yalei Chen; Rishi R Bakshi
Journal:  BMC Health Serv Res       Date:  2022-04-15       Impact factor: 2.908

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.